EFNS Guidelines on diagnosis and treatment of brain metastases: Report of an EFNS Task Force

European Journal of Neurology

Volumn 13, Issue 7, 2006, Pages 674-681

  Soffietti, R ^a   Cornu, P ^b   Delattre, J Y ^b   Grant, R ^c   Graus, F ^d   Grisold, W ^e   Heimans, J ^f   Hildebrand, J ^g   Hoskin, P ^h   Kalljo, M ⁱ   Krauseneck, P ^j   Marosi, C ^k   Siegal, T ^l   Vecht, C ^m  

^a MOLINETTE HOSPITAL   (Italy)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

^d HOSPITAL CLÍNIC   (Spain)

^e KAISER FRANZ JOSEF HOSPITAL   (Austria)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g Academisch Ziekenhuis VU ^*

^h MOUNT VERNON HOSPITAL   (United Kingdom)

ⁱ HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^j Vienna General Hospital and University   (Germany)

^k UNIVERSITY OF VIENNA   (Austria)

^l HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^m MEDICAL CENTER HAAGLANDEN   (Netherlands)

more..

Author keywords

Brain metastases; Diagnosis; Evidence based guidelines; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; CORTICOSTEROID; DEXAMETHASONE;

ARTICLE; BRAIN EDEMA; BRAIN METASTASIS; BRAIN RADIOGRAPHY; BRAIN TUMOR; CANCER CHEMOTHERAPY; CHEMOSENSITIVITY; COMPUTER ASSISTED TOMOGRAPHY; EVIDENCE BASED MEDICINE; HUMAN; HUMAN TISSUE; INFORMATION PROCESSING; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIOSURGERY; SAFETY;

ADVISORY COMMITTEES; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; EUROPE; EVIDENCE-BASED MEDICINE; HUMANS; MAGNETIC RESONANCE IMAGING; MEDLINE; NEOPLASM METASTASIS; NEUROSURGERY; RADIOSURGERY; RADIOTHERAPY, CONFORMAL; SOCIETIES, MEDICAL; TREATMENT OUTCOME;

EID: 33746555944     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2006.01506.x     Document Type: Article

References (44)

1. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. International Journal of Radiation Oncology, Biology, Physics 1997; 37: 745-751.
2. Lagerwaard FJ, Levendag PC, Nowak PJ, et al. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. International Journal of Radiation Oncology, Biology, Physics 1999; 43: 795-803.
3. Murray KJ, Scott C, Zachariah B et al. Importance of the Mini-Mental Status Examination in the treatment of patients with brain metastases: a report from the Radiation Therapy Oncology Group protocol. International Journal of Radiation Oncology, Biology, Physics 2000; 48: 59-64.
4. Meyers CA, Smith JA, Bezjak A. Neurocognitive function and progression in patients with brain metastases treated with whole brain radiation and motexafin gadolinium: results of a randomized phase III trial. Journal of Clinical Oncology 2004; 22: 157-165.
5. Rudà R, Borgognone M, Benech F, et al. Brain metastases from unknown primary tumor. Journal of Neurology 2001; 248: 394-398.
6. Brainin M, Barnes M, Baron JC, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2004. European Journal of Neurology 2004; 11: 577-581.
7. Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CT in patients with brain metastases. Journal of Neuro-Oncology 1999; 44: 275-281.
8. Sze G, Johnson C, Kawamura Y, et al. Comparison of single- and triple-dose contrast material in the MR screening of brain metastases. American Journal of Neuroradiology 1998; 19: 821-828.
9. Desprechins B, Stadnik T, Koerts G, et al. Use of diffusion-weighted MR imaging in the differential diagnosis between intracerebral necrotic tumors and cerebral abscesses. American Journal of Neuroradiology 1999; 20: 1252-1257.
10. Hartmann M, Jansen O, Heiland S, et al. Restricted diffusion within ring enhancement is not pathognomonic for brain abscess. American Journal of Neuroradiology 2001; 22: 1738-1742.
11. Van de Pol M, van Aalst VC, Wilmink JT et al. Brain metastases from an unknown primary tumor: which diagnostic procedures are indicated? Journal of Neurology, Neurosurgery and Psychiatry 1996; 61: 321-323.
12. Klee B, Law I, Hoigaard L, Kosteljanetz M. Detection of unknown primary tumours in patients with cerebral metastases using whole-body 18F-fluorodeoxyglucose positron emission tomography. European Journal of Neurology 2002; 9: 657-662.
13. Vecht CJ, Hovestadt A, Verbiest HB, et al. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology 1994; 44: 675-680.
14. Cairncross JG, Posner JB. The management of brain metastases. In: Walker MD, ed. Oncology of the Nervous System. Boston, MA: Martinus Nijhoff, 1983: 342-377.
15. Glantz MJ, Cole BF, Forsyth PA et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 54: 1886-1893.
16. Kuijlen JM, Teernstra OP, Kessels AG, et al. Effectiveness of antiepileptic prophylaxis used with supratentorial craniotomies: a meta-analysis. Seizure 1996; 5: 291-298.
17. Gould MK, Dembitzer AD, Doyle RL, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Annals of Internal Medicine 1999; 130: 800-809.
18. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus coumarin for the prevention of recurrent venous thromboembolism in cancer. New England Journal of Medicine 2003; 349: 146-153.
19. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. New England Journal of Medicine 1990; 322: 494-500.
20. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Annals of Neurology 1993; 33: 583-590.
21. Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996; 78: 1470-1476.
22. Black PM, Johnson MD. Surgical resection for patients with solid brain metastases: current status. Journal of Neuro-Oncology 2004; 69: 119-124.
23. Kelly K, Bunn PA. It is time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer? Lung Cancer 1998; 20: 85-91.
24. Warnick RE, Darakchiev BJ, Breneman JC. Stereotactic radiosurgery for patients with solid brain metastases: current status. Journal of Neuro-Oncology 2004; 69: 125-137.
25. Soffietti R, Costanza A, Laguzzi E, et al. Radiotherapy and chemotherapy of brain metastases. Journal of Neuro-Oncology 2005; 75: 1-12.
26. Sneed PK, Suh JH, Goetsch SJ, et al. A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. International Journal of Radiation Oncology, Biology, Physics 2002; 53: 519-526.
27. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG randomised trial. Lancet 2004; 363: 1665-1672.
28. Shaw E, Scott C, Souhami L, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. International Journal of Radiation Oncology, Biology, Physics 2000; 47: 291-298.
29. Gelblum DY, Lee H, Bilsky M, Pinola C, Longford S, Wallner K. Radiographic findings and morbidity in patients treated with stereotactic radiosurgery. International Journal of Radiation Oncology, Biology, Physics 1998; 42: 391-395.
30. Chao ST, Suh JH, Raja S, et al. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. International Journal of Cancer 2001; 96: 191-197.
31. Rock JP, Scarpace L, Hearshen D, et al. Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopatology with special attention to radiation necrosis. Neurosurgery 2004; 54: 1111-1117.
32. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single brain metastases to the brain. The Journal of the American Medical Association 1998; 280: 1485-1489.
33. Pirzkall A, Debus J, Lohr F, et al. Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases. Journal of Clinical Oncology 1998; 16: 3563-3569.
34. De Angelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology 1989; 39: 789-796.
35. Borgelt BB, Gelber RD, Kramer S, et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. International Journal of Radiation Oncology, Biology, Physics 1980; 6: 1-9.
36. Hoskin PJ, Brada M. Radiotherapy for brain metastases. Clinical Oncology 2001; 13: 91-94.
37. Metha M, Rodrigus P, Terhaard C, et al. Survival and neurologic outcomes in a randomized trial of motexafin-gadolinium and whole-brain radiation therapy in brain metastases. Journal of Clinical Oncology 2003; 21: 2529-2536.
38. Shaw E, Scott C, Suh J et al. RSR 13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group recursive partitioning analysis brain metastases database. Journal of Clinical Oncology 2003; 21: 2364-2371.
39. Pollock BE, Brown PD, Foote RL et al. Properly selected patients with multiple brain metastases may benefit from aggressive treatment of their intracranial disease. Journal of Neuro-Oncology 2003; 61: 73-80.
40. Robinet G, Thomas P, Breton JL, et al. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastases of non-small cell lung cancer: Groupe Francais de Pneumocancerologie (GFPC) protocol 95-1. Annals of Oncology 2001; 12: 59-67.
41. Antonadou D, Paraskevaidis M, Sarris G et al. Phase 2 randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. Journal of Clinical Oncology 2002; 20: 3644-3650.
42. Verger E, Gil M, Yaya R et al. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase 2 trial. International Journal of Radiation Oncology, Biology, Physics 2005; 61: 185-191.
43. Rogers LR, Rock JR, Sills A et al. Final results of a phase II study of resection and gliasite brachytherapy for a single brain metastasis. Neuro-Oncology 2004; 6: 363.
44. Ceresoli G, Cappuzzo F, Gregorc V et al. Gefitinib in patients with brain metastases from non-small cell lung cancer: a prospective trial. Annals of Oncology 2004; 15: 1042-1047.